This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Nevro (NVRO) 주식 개요
의료 기기 회사인 Nevro는 미국 및 전 세계에서 만성 통증으로 고통받는 환자를 위한 제품을 공급하는 기업입니다. 자세히 보기
NVRO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Nevro Corp. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$5.84 |
| 52주 최고가 | US$13.84 |
| 52주 최저가 | US$3.17 |
| 베타 | 0.82 |
| 1개월 변동 | 0.86% |
| 3개월 변동 | 57.41% |
| 1년 변동 | -56.06% |
| 3년 변동 | -92.38% |
| 5년 변동 | -94.65% |
| IPO 이후 변동 | -76.82% |
최근 뉴스 및 업데이트
Recent updates
새로운 내러티브 • Apr 03
Restructuring And AI Trials Will Advance Spinal Cord Stimulation
Strategic expense management and resource reallocation could enhance profitability and revenue, particularly through improved net margins and increased U.S. market activity.분석 기사 • Jan 23
Nevro Corp.'s (NYSE:NVRO) Price Is Right But Growth Is Lacking After Shares Rocket 30%
Nevro Corp. ( NYSE:NVRO ) shares have had a really impressive month, gaining 30% after a shaky period beforehand...분석 기사 • Aug 11
Little Excitement Around Nevro Corp.'s (NYSE:NVRO) Revenues As Shares Take 34% Pounding
The Nevro Corp. ( NYSE:NVRO ) share price has fared very poorly over the last month, falling by a substantial 34%. The...Seeking Alpha • Aug 09
Nevro: Not Having My Back
Summary Nevro Corp.'s shares hit fresh lows after revenue guidance reset, reflecting stagnant growth and substantial losses. The company has seen an eventful decade with huge share price fluctuations, but the situation is quite severe right now. Competitive pressures hurt the topline sales, as the loss rate is very substantial, leaving few opportunities to grow out of this situation here. Read the full article on Seeking Alpha분석 기사 • Jul 16
Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • May 01
Nevro Corp. (NYSE:NVRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
To the annoyance of some shareholders, Nevro Corp. ( NYSE:NVRO ) shares are down a considerable 27% in the last month...분석 기사 • Feb 25
Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Jan 08
There Is A Reason Nevro Corp.'s (NYSE:NVRO) Price Is Undemanding
With a price-to-sales (or "P/S") ratio of 1.7x Nevro Corp. ( NYSE:NVRO ) may be sending bullish signals at the moment...분석 기사 • Nov 16
Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • Sep 01
Nevro: Economic Realities Too Deep To Ignore, Downgrade To Hold
Summary Nevro Corp. shares have significantly underperformed, selling 57% lower than in 2021. The company's top-line momentum continues, but it faces economic challenges and lacks value creation for shareholders. As a positive, NVRO's Q2 FY'23 showed significant growth in painful diabetic neuropathy revenues. Net-net, revise to hold. Read the full article on Seeking Alpha분석 기사 • Jul 10
Nevro (NYSE:NVRO) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Feb 28
Investors Shouldn't Be Too Comfortable With Nevro's (NYSE:NVRO) Robust Earnings
Despite announcing strong earnings, Nevro Corp.'s ( NYSE:NVRO ) stock was sluggish. Our analysis uncovered some...Seeking Alpha • Feb 22
Nevro falls to 52-week low; down ~49% over last year
Medical device company Nevro (NYSE:NVRO) hit a 52-week low of $33.36 on Wednesday afternoon. Over the last year, the stock is down ~49%. In 2022, the company, known for its Senza spinal cord stimulation system, a neuromodulation platform for chronic pain, saw its revenue increase year-over-year. However, it only eked out $3M in net income for the year. Seeking Alpha contributor The Value Investor calls Nevro (NVRO) a hold as it has demonstrated a lack of growth.Seeking Alpha • Feb 14
Nevro: Treating Patient Back Pains, Causing Shareholder Back Pains
Summary Nevro Corp. has seen multiple boom-bust cycles in its share price, and we are in the bust phase again. Unlike previous times, the Nevro Corp. growth story has been impaired, with revenues stable for a while now. Sales multiples look reasonable, but lack of growth and large losses make it hard to become upbeat about Nevro Corp. stock. When Nevro Corp. (NVRO) went public late in 2014, I urged a cautious tone on NVRO shares after the pain-relief company had seen a successful public debut. Shares rose as much as 50% on their first day of trading, with investors pricing in the prospects for adoption of its chronic pain treatment in the U.S. The higher valuation in relation to a somewhat modest addressable market made me a bit cautious. Back To 2014 When Nevro went public, investors were upbeat on the prospects for the business. It had developed the so-called Spenza system, the only spinal cord stimulation (at least at the time), used for the treatment of back and leg pain. These two segments represented a large $1.5 billion global market segment after the company obtained pre-market approval by the FDA in 2014, with commercial launch seen in 2016. This came after Spenza was already available in Europe in 2010 and in Australia a year later. Nevro Corp. shares went public at $18 per share, two dollars above the midpoint of the preliminary offering range. The shares immediately rose to the $25 mark, granting the company a market value in excess of half a billion, including a substantial net cash position of around $150 million. Based on the limited user base at the time, Nevro posted sales of $23 million in 2013, as losses of $26 million exceeded the revenue base. Revenues rose 28% in the first half of 2014, trending at a rate of $28 million, as losses were stable, running at a rate equal to reported sales. The potential, of course, was the launch in the U.S., although that same launch and burn rate would create a significant cash burn, creating quite an uncertain situation. All of this made me a bit cautious. Working Out, Then Not So Much Nevro Corp. stock has been a huge success, as shares hit the $100 mark in 2016. Thereafter, they fell back to the $40 mark in 2019 and rallied to $180 late in 2020. Ever since, shares have gradually come down to $35 per share again. Forwarding to early 2019, we have seen that Nevro has seen a successful launch in the U.S. 2018 sales rose nearly 20% to $387 million, of which the vast majority being generated in the U.S. following a successful commercial launch. While that is promising, the company still posted a GAAP operating loss of $41 million and change, as the company has been posting losses since the public offering. Moreover, Nevro Corp. has seen continued dilution, with the share count being up to 30 million in the meantime. Forwarding to spring 2022, Nevro posted $387 million in 2021 sales, being dead flat compared to 2018, after showing a modest recovery from the 2020 sales multiples which were impacted by the pandemic. Operating losses rose to $111 million, and even if I kindly exclude a $20 million litigation charge, losses were up sharply from a $63 million loss in 2020 (and losses posted before). These losses and some stock sales (or at least dilution) meant that the share count has risen to 35 million shares here, as the company maintained a modest net cash position. After peak valuations topped $7 billion, the equity valuation came down to $2.6 billion at $75 per share early in 2022, still translating into demanding multiples given the lack of growth and substantial losses. For 2022, the company guided for sales between $415 and $430 million, expecting adjusted EBITDA losses between $8 and $18 million, hardly set to make an improvement from a $17 million loss posted in 2021. Through the first three quarters of 2022, Nevro has posted stable results. Revenues were up less than 3% to $293 million for the first three quarters, as a litigation benefit of $105 million (received from Boston Scientific (BSX)) was responsible for an operating loss of $25 million, as otherwise, losses would be pretty flat. By now full year sales are seen at a midpoint of $405 million, with the shortfall mostly due to the strong dollar, with the midpoint of the EBITDA losses now seen at $21 million. The 37 million shares now granted the business a $1.3 billion equity valuation, including a $200 million net cash position. Adjusted for this, an enterprise value of $1.1 billion works down to less than 3 times sales, although the real issue is a lack of growth and continued losses.분석 기사 • Jan 13
Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Seeking Alpha • Dec 07
Nevro: Opportunity Overshadowed By Weaknesses
Summary Nevro is a company that has developed a spinal cord stimulation implant to treat chronic pain. The FDA approved device is implanted into the back and has a good amount of clinical data to support the efficacy. Future growth relies on expanded geography, utilization, and the addition of new indications for various types of chronic pain. Introduction One of the least understood forms of chronic pain are related to non-surgical back and leg pain. There is also a significant population of patients who suffer from painful diabetic neuropathy that is hard to treat. These are markets that the FDA has approved Nevro (NVRO) to treat with direct electrical stimulation to the spinal cord. Now, patients who have been unable to cure their chronic pain issues have a new way to attempt to find peace. For Nevro, the path to full approval of their product has been in the works for over a decade, with limited use allowed in years prior. Growth really took off from 2015 to 2018, but has plateaued since, partially due to the pandemic limiting marketing the products and elective procedures. Also, the company has failed to find profitability despite the ~$100 million in quarterly revenues, primarily due to capital expenses and funding numerous trials. Investors must consider this when considering the investment, but I will share my thoughts on the potential by the end of the article. Nevro Q3 Presentation Nevro's Device - The Key to Success As discussed, Nevro's uses electrostimulation to influence the nervous system and attempt to reduce pain. Their platform involves implanting a device that directly inserts leads into the spinal cord to target various frequencies depending on the setting. Over the years, the company has collected enough data to create an AI-led platform that optimizes a patient's treatment based on their needs. This new software platform is expected to be fully released by 2023 and will likely boost sales if patients believe the personalization is worthwhile. So far, so good, if early clinical results are representative. Nevro Q3 Presentation Nevro Q3 Presentation I think it is important now to address the elephant in the room. As is common in the medical device and equipment industry, litigation has been an issue for Nevro over the past few years. In fact, this includes a patent battle against Boston Scientific (BSX) that has recently been settled and Nevro won $85 million. This is despite losing in front of a jury a few years ago and signals an end to this overhang. The influx of cash also helps Nevro take those final steps towards profitability. Although, there is still some risk remaining as BSX remains the main competitor in the neuromodulation market. Due to this fact, when BSX sees a weak sales environment, so will Nevro. This has been the case even into 2022 with sales remaining flat for years. According to managerial comments, the issue seems to be less related to physician willingness or a lack of patients, but with insurance coverage and payment. As per a SA news article: Commenting on Spinal Cord Stimulator ((SCS)) Systems, Chief Executive Mike Mahoney said that despite solid international growth, "US SCS sales were impacted by preauthorization denials despite strong patient demand and ongoing physician interest in our fast therapy." The lack of sales growth for years across the industry is a real bad sign for Nevro because they are missing out on at least a $2.0 billion market spinal stimulation market. When considering general chronic pain issues, and not just the spinal cord stimulation market, the TAM looks to be over $15 billion per year. Certainly, investors can expect that there is plenty of room to grow, the issue will be penetration and execution. Nevro Q3 Presentation Koyfin One Area of Growth A newly expanded indication into painful diabetic neuropathy, or PDN, is the one small niche that is seeing noteworthy growth for Nevro. With a TAM of approximately $3-5 billion, this segment could hold NVRO's current valuation on its own even if the other indications fail to provide growth. However, it is still the early innings as quarterly revenues have not even reached $15 million. Thankfully, there seems to be better insurance coverage for this segment and I expect the growth to continue rapidly over the coming years. Nevro Q3 Presentation Nevro Q3 Presentation Nevro Q3 Presentation Financials As shown in a prior chart, revenue growth has flattened over the past few years. At the same time, losses have continued at an average of 20-50% quarterly EBITDA losses. Apart from a few influxes of cash from litigation or investments, Nevro is operating at a serial loss and no improvement to the trend can be seen at the moment. The recent boost of cash from the BSX settlement certainly helps, especially when looking from the lens of the balance sheet. Koyfin From the payment, cash on hand raised to a respectable $387 million as of the last earnings report, and this allows for an operational runway of 15 quarters, or just about 4 years. However, shareholders are not fans of the increases in debt and dilution that have helped to provide operation cash, although bankruptcy is far worse than debt and dilution. However, one positive development to consider is the fact that the creation of a manufacturing facility in Costa Rica is now complete and FDA approved, so capex spending is likely to fall moving forward. Combined with the expected return to growth over the next few quarters, I believe that profitability will increase, which will in turn improve FCF and the health of the balance sheet.Seeking Alpha • Oct 26
Boston Scientific drives rival Nevro lower after remarks on neuromodulation
Nevro Corp. (NYSE:NVRO), a company focused on neuromodulation solutions, dropped at the open on Wednesday after its rival Boston Scientific (BSX) said that its Q3 sales for the pain treatment fell short of expectations. Boston Scientific’s (BSX) neuromodulation business markets products to address neurological movement disorders and manage chronic pain. However, the segment with $221M in net sales remained stagnant during the quarter, and the management attributed the underperformance to ongoing reimbursement challenges impacting the U.S. procedures. “Commenting on Spinal Cord Stimulator (SCS) Systems, Chief Executive Mike Mahoney said that despite solid international growth, “US SCS sales were impacted by preauthorization denials despite strong patient demand and ongoing physician interest in our fast therapy.” Nevro (NVRO) generated more than ~84% of revenue from the U.S. in 2021.Seeking Alpha • Oct 13
Nevro's Senza spinal cord stimulation system for chronic pain gets FDA approval
The U.S. Food and Drug Administration (FDA) approved Nevro's (NYSE:NVRO) Senza HFX iQ spinal cord stimulation (SCS) system. Senza HFX iQ is the first and only Artificial Intelligence (AI)-based SCS system which learns from patients, the company said in an Oct. 12 press release. Nevro noted that the the system was developed to address the variability in pain from patient to patient and to help patients optimize and maintain long-term pain relief. The system consists of the HFX iQ Implantable Pulse Generator (IPG), HFX Trial Stimulator, charger and HFX App and will launch with algorithms specifically for treating chronic back and leg pain, including non-surgical back pain and painful diabetic neuropathy. Nevro will start a limited release of the device in the U.S. this quarter, with a broad U.S. market launch planned for early 2023. The company noted that it has also filed for approval in Europe.주주 수익률
| NVRO | US Medical Equipment | US 시장 | |
|---|---|---|---|
| 7D | 0% | 0.3% | 2.5% |
| 1Y | -56.1% | -19.6% | 26.4% |
수익률 대 산업: NVRO은 지난 1년 동안 -19.6%의 수익을 기록한 US Medical Equipment 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: NVRO은 지난 1년 동안 26.4%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| NVRO volatility | |
|---|---|
| NVRO Average Weekly Movement | 9.8% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.1% |
안정적인 주가: NVRO는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: NVRO의 주간 변동성(10%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2006 | 1,099 | Kevin Thornal | nevro.com |
의료 기기 회사인 Nevro는 미국 및 전 세계에서 만성 통증으로 고통받는 환자를 위한 제품을 공급하는 회사입니다. 이 회사는 감각 이상이 없는 10kHz 치료를 통해 만성 요통 및 다리 통증을 치료하는 증거 기반 신경조절 시스템인 Senza SCS 시스템을 포함한 HFX 척수 자극(SCS) 플랫폼을 제공하며, Senza II 및 Senza Omnia SCS 시스템도 제공합니다. 또한 HFX iQ 이식형 펄스 발생기, HFX 시험 자극기, HFX iQ 환자 리모컨, 환자 원격 제어 및 무선 시험 시스템인 HFX 앱이 포함된 Senza HFX iQ 플랫폼을 제공합니다.
Nevro Corp. 기초 지표 요약
| NVRO 기초 통계 | |
|---|---|
| 시가총액 | US$221.21m |
| 순이익 (TTM) | -US$113.44m |
| 매출 (TTM) | US$408.52m |
0.5x
주가매출비율(P/S)-2.0x
주가수익비율(P/E)NVRO는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| NVRO 손익계산서 (TTM) | |
|---|---|
| 매출 | US$408.52m |
| 매출원가 | US$138.99m |
| 총이익 | US$269.53m |
| 기타 비용 | US$382.97m |
| 순이익 | -US$113.44m |
최근 보고된 실적
Dec 31, 2024
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -2.99 |
| 총이익률 | 65.98% |
| 순이익률 | -27.77% |
| 부채/자본 비율 | 97.7% |
NVRO의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2025/04/04 00:31 |
| 종가 | 2025/04/02 00:00 |
| 수익 | 2024/12/31 |
| 연간 수익 | 2024/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Nevro Corp.는 8명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Joanne Wuensch | BMO Capital Markets Equity Research |
| Gregory Chodaczek | B. Riley Securities, Inc. |
| David Turkaly | Citizens JMP Securities, LLC |